OMO-1 in Solid Malignancies

Summary

This is a modular, first time in patient, open-label, multicentre study of OMO-1, administered orally, alone and in combination with anti-cancer treatments, in patients with locally advanced, unresectable or metastatic solid malignancies.

Timeline

Start

2017-08-08

Primary completion

2020-05-25

Completion

2020-05-25

Outcome

Outcome not reported

Stopped (Business): “strategic reasons (not due to lack of efficacy or safety issues)”

Drugs

Indications